Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
OFIX 
Orthofix Medical Inc (OFIX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: OFIX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $22.3
1 Year Target Price $22.3
| 2 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -63.49% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 435.69M USD | Price to earnings Ratio - | 1Y Target Price 22.3 |
Price to earnings Ratio - | 1Y Target Price 22.3 | ||
Volume (30-day avg) 5 | Beta 0.81 | 52 Weeks Range 10.24 - 20.73 | Updated Date 07/4/2025 |
52 Weeks Range 10.24 - 20.73 | Updated Date 07/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.7 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -17.78% | Operating Margin (TTM) -17.64% |
Management Effectiveness
Return on Assets (TTM) -5% | Return on Equity (TTM) -27.82% |
Valuation
Trailing PE - | Forward PE 20.04 | Enterprise Value 567558300 | Price to Sales(TTM) 0.54 |
Enterprise Value 567558300 | Price to Sales(TTM) 0.54 | ||
Enterprise Value to Revenue 0.71 | Enterprise Value to EBITDA 34.53 | Shares Outstanding 39180800 | Shares Floating 38609185 |
Shares Outstanding 39180800 | Shares Floating 38609185 | ||
Percent Insiders 2.79 | Percent Institutions 87.79 |
Upturn AI SWOT
Orthofix Medical Inc
Company Overview
History and Background
Orthofix Medical Inc. was founded in 1980. Initially focused on external fixation, the company has grown through acquisitions and product development to offer a wider range of orthopedic and spine solutions. A significant milestone was the merger with SeaSpine in January 2023.
Core Business Areas
- Spine Fixation: Develops and markets a comprehensive portfolio of spine fixation products, including thoracolumbar fixation, cervical fixation, interbody implants, and motion preservation systems.
- Biologics: Offers a range of bone growth stimulation and regenerative solutions, including bone graft substitutes, cellular bone allografts, and growth factors.
- Orthopedics: Provides orthopedic solutions focused on fracture management, limb reconstruction, and bone regeneration.
- Bone Growth Therapies: Solutions to help patients heal fractures and stimulate bone growth.
Leadership and Structure
The company is led by a board of directors and an executive management team. The organizational structure is typical of a publicly traded medical device company, with functional departments like R&D, marketing, sales, operations, and finance. SerSpine CEO, Keith Valentine, is the CEO of the merged company, and the board is a combination of former Orthofix and SeaSpine board members.
Top Products and Market Share
Key Offerings
- M6-C Artificial Cervical Disc: A motion-preserving device for cervical disc replacement. Competitors include Medtronic (MDT) and Johnson & Johnson (JNJ). Market share data is difficult to find for specific products, but the overall cervical disc market is competitive.
- FORZA XP Expandable Interbody System: An expandable interbody device used in spinal fusion surgeries. Competitors include Stryker (SYK) and NuVasive (NUVA). Again, specific market share data is hard to obtain, but expandable interbody devices are a growing segment.
- Physiostim: A bone growth stimulator for fracture healing. Market share is estimated at approximately 20% in the bone growth stimulation market. Competitors include DJO Global.
Market Dynamics
Industry Overview
The orthopedic and spine market is a large and growing market driven by an aging population, increasing prevalence of orthopedic conditions, and advancements in technology. The market is competitive, with several large players and smaller specialized companies.
Positioning
Orthofix is positioned as a mid-sized player in the orthopedic and spine market, with a focus on innovation and a comprehensive product portfolio. The merger with SeaSpine aimed to create a stronger, more diversified company.
Total Addressable Market (TAM)
The global orthopedic devices market is estimated to reach over $60 billion by 2028. Orthofix, with projected revenues in the hundreds of millions, has a small but meaningful position in the overall TAM and has opportunity to grow.
Upturn SWOT Analysis
Strengths
- Comprehensive product portfolio
- Strong brand reputation
- Established distribution network
- Innovative product pipeline
- Strong leadership team post-merger
Weaknesses
- Smaller market share compared to larger competitors
- Integration challenges post-merger
- Dependence on new product launches
- Relatively high debt levels
Opportunities
- Expanding into emerging markets
- Developing new technologies and products
- Acquiring complementary businesses
- Increasing adoption of minimally invasive surgery
- Capitalizing on the growing aging population
Threats
- Intense competition
- Pricing pressures
- Regulatory changes
- Product liability claims
- Economic downturns
Competitors and Market Share
Key Competitors
- MDT
- JNJ
- SYK
- NUVA
- BSX
Competitive Landscape
Orthofix faces competition from larger, more established players in the orthopedic and spine market. The company's competitive advantage lies in its comprehensive product portfolio, focus on innovation, and strong relationships with surgeons. However, the integration post SeaSpine merger is critical.
Major Acquisitions
SeaSpine
- Year: 2023
- Acquisition Price (USD millions): 0
- Strategic Rationale: Merger of equals intended to create a leading global spine and orthopedic company with a more comprehensive product portfolio, expanded distribution network, and enhanced growth opportunities.
Growth Trajectory and Initiatives
Historical Growth: Orthofix has grown organically and through acquisitions. The merger with SeaSpine is expected to accelerate growth.
Future Projections: Analyst estimates vary. Post-merger synergies and new product launches are key drivers for future growth. Look for company guidance post-merger.
Recent Initiatives: The most significant recent initiative is the merger with SeaSpine. Other initiatives may include new product launches, strategic partnerships, and expansion into new markets.
Summary
Orthofix is a mid-sized player in the orthopedic and spine market that completed a merger with SeaSpine. The merger aims to create a larger, more competitive company. Key strengths include a comprehensive product portfolio and innovative pipeline. The company must effectively integrate SeaSpine and address debt to realize the full benefits of the merger.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (10-K, 10-Q)
- Industry reports
- Analyst estimates
- Press releases
- Company Website
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market conditions and company performance are subject to change. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Orthofix Medical Inc
Exchange NASDAQ | Headquaters Lewisville, TX, United States | ||
IPO Launch date 1992-04-24 | President, CEO & Director Mr. Massimo Calafiore | ||
Sector Healthcare | Industry Medical Devices | Full time employees 1616 | Website https://orthofix.com |
Full time employees 1616 | Website https://orthofix.com | ||
Orthofix Medical Inc. operates as a medical technology company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulation devices that enhance bone fusion, including adjunctive and noninvasive treatment of the cervical and lumbar spine, as well as a therapeutic treatment for non-spinal, appendicular fractures, and fresh fractures that have not healed; designs, develops, and markets a portfolio of spine fixation and motion preservation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal, orthopedic, and dental conditions. This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations; and provides 7D flash navigation system for spine and cranial procedures. Its Global Orthopedics segment offers products and solutions that allow physicians to treat various orthopedic conditions related to limb reconstruction and deformity correction unrelated to the spine. This segment designs, develops, and markets external and internal fixation orthopedic products that are coupled with enabling digital technologies to serve the complete patient treatment pathway. It sells its products through distributors and sales representatives to hospitals, healthcare organizations, and healthcare providers. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.